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type of graft under investigation. Combined treatments with 
other immunosuppressive agents are now under investigation 
in our laboratory. 
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HYPERACUTE REJECTION OF A TRANSPLANTED HUMAN HEARTl 
The possibility of hyperacute rejection has not generally been 
considered an important concern in human cardiac transplan-
tation. Cardiac replacement is often carried out under time 
constraints which make histocompatibility testing impractical. 
The donor heart may be harvested hundreds of miles away 
from the recipient, and the limited period of safe cardiac pres-
ervation then argues against taking time for direct lymphocyte 
crossmatching of donor with recipient before the transplant 
operation is done (1). 
A patient is reported in whom hyperacute cardiac rejection 
occurred on the operating table. The direct lymphocyte cross-
match test, which was not completed preoperatively, subse-
quently showed that the recipient had performed cytotoxic 
antibodies which reacted strongly against donor lymphocytes. 
A 56-year-old woman developed cardiogenic shock following 
recurrent myocardial infarction. She initially required intra-
aortic balloon support. transvenous pacemaker, and vasopres-
sors for survival. Although gradual withdrawal of some of these 
support measures was possible, she nevertheless remained he-
modynamically unstable and bedridden with intractable con-
gestive heart failure. Cardiac catheterization revealed severe 
left ventricular dysfunction with ejection fraction of less than 
20% of predicted normal. Coronary angiography demonstrated 
three vessel disease with distal involvement not amenable to 
coronary artery bypass. The referring cardiologist requested 
urgent cardiac transplantation as the only possible way of 
saving the patient. 
A young ABO compatible brain-dead donor became available 
almost immediately, and heart replacement was carried out 
using a surgical technique of Shumway (2). The donor heart 
was preserved by perfusion with cold cardioplegia solution (3). 
Total ischemia time was 7() min. Spontaneous donor heart beat 
began very quickly after removal of the aortic cross clamp. No 
technical problems with any of the anastomoses or with trapped 
air were evident as total bypass was discontinued. 
Approximately 15 min after partial cardiopulmonary bypass 
Was established, the heart suddenly became asystolic, mottled, 
and cyanotic. Total cardiopulmonary bypass was reinstituted 
and atrial ventricular sequential pacing was started via epicar-
dial atrial and ventricular wires. Isuprel and epinephrine were 
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administered and 1 g of methylprednisolone was given i.v. 
These temporarily improved cardiac function and cardiopul-
monary bypass was discontinued with the heart beating in 
normal sinus rhythm. Three additional bolus doses of 1 g of 
methylprednisolone were given. At the conclusion of the oper-
ation, cardiac output again fell and a dopamine drip was started. 
Approximately 2 hr later, an intra-aortic balloon was inserted 
because of persistently low cardiac output. The patient died in 
intractable cardiogenic shock approximately 4 hr after opera-
tion. 
A direct crossmatch between the patient's serum and the 
donor's lymphocytes, done at room temperature without sepa-
ration of donor cells into Band T lymphocytes, revealed 100% 
killing of donor cells by the recipient's serum. This test was not 
completed until after the heart transplant was fmished. Sub-
sequent postmortem lymphocytotoxicity testing of the recipi-
ent's serum was done to better characterize the recipient anti-
bodies. 
Band T lymphocytes were isolated by nylon-wool column 
and tested using the standard lymphocyte microtoxicity test 
(4). When the pre transplant serum was tested against a panel 
of T and B lymphocytes at different temperatures, 33% of the 
panel of T lymphocytes was completely killed by the serum. 
The power of these kill reactions strongly suggests that the 
patient had antibodies to T lymphocytes. The test panel con-
sisted of lymphocytes from 24 normal patients. When tested 
against B lymphocytes, the pretransplant serum reacted with 
42% of the panel at 37 C and 25% of the B cell panel at 5 C. 
Thus, both the T cell and B cell reactivity was mostly produced 
by warm-reactive antibodies. In order to determine whether 
the antibodies might be against HLA-DR or ABC, the serum 
was absorbed with pooled platelets. All of the reactivity was 
removed by platelets, indicating that the antibodies were 
against HLA-ABC antigens. 
At autopsy, microscopy of the donor heart revealed diffuse 
interstitial edema and some focal hemorrhage. Small arteries, 
arterioles, capillaries, and venules were extensively plugged by 
platelet aggregates. There were also some intravascular fibrin 
and sludged red blood cells. Marginating neutrophil polymor-
phonuclear leukocytes were also present within the capillaries 
and venules. Some capillaries were disrupted. Mononuclear 
cells were rare. These microscopic findings were interpreted as 
hyperacute rejection. 
Acute rejection of heart transplants, mediated primarily by 
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T lymphocytes, has been observed on many occasions in ani-
mals and in humans (2. 5-111. Hyperacute heart rejection 
mediated by preformed cytotoxic antibody has been described 
in cross species heart transplantation (12) and in cardiac allo-
grafts in dogs (1:3) and rats (]4). when the recipients had been 
presensitized. Up to now it has not been reported in human 
heart transplants. 
In this case the patient's very unstable blood pressure. com-
bined with our perception that hyperacute rejection was a very 
unlikely possibility, led us to proceed with heart replacement 
without waiting for the results of the direct crossmatch test. 
The patient's cardiogenic shock was so resistant to treatment 
that she almost certainly could not have survived long enough 
to wait for a crossmatch-negative heart donor, even if the 
results of the crossmatch with the actual donor had been known 
before transplantation. However, the predictive value of the 
crossmatch test is evident in this case and represents an obser-
vation which is clinically important for heart transplant recip-
ients who are hemodynamically stable enough to wait for a 
crossmatch-negative donor. 
At the time of the original crossmatch, the serum was not 
tested against Band T lymphocytes. There are indications that 
a crossmatch reactive against B lymphocytes does not result in 
a hyperacute rejection in kidney transplants (15). In this in-
stance, it was not possible to retrospectively determine whether 
the positive crossmatch obtained was against T or B cells. 
However, the fact that all of the donor cells were killed by the 
patient's serum indicates that a T cell-positive crossmatch had 
been obtained. Subsequent tests with Band T cell panels also 
suggest that this indeed was a positive T cell crossmatch. The 
patient had antibodies to both T and B cells, but since this 
activity could all be removed by platelets, it is likely that HLA-
ABC antibodies were involved and not HLA-DR antibodies. 
Although there was not so much interstitial hemorrhage in 
the transplanted heart as has been described in cardiac allo-
grafts in presensitized dogs (13) and rats (14), the microscopic 
findings are entirely consistent with the clinical diagnosis of 
hyperacute rejection. 
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